Published in J Heart Lung Transplant on March 16, 2011
Immune response to tissue-restricted self-antigens induces airway inflammation and fibrosis following murine lung transplantation. Am J Transplant (2014) 1.56
Antibodies to K-α 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant (2012) 1.19
The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol (2012) 1.03
Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol (2013) 1.02
Role of complement activation in obliterative bronchiolitis post-lung transplantation. J Immunol (2013) 1.01
IL-17 induces type V collagen overexpression and EMT via TGF-β-dependent pathways in obliterative bronchiolitis. Am J Physiol Lung Cell Mol Physiol (2012) 0.99
Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. Semin Respir Crit Care Med (2013) 0.98
Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. Am J Respir Crit Care Med (2014) 0.94
T regulatory cells play a significant role in modulating MHC class I antibody-induced obliterative airway disease. Am J Transplant (2012) 0.92
Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant (2014) 0.91
Donor-Derived Exosomes With Lung Self-Antigens in Human Lung Allograft Rejection. Am J Transplant (2016) 0.91
An important role for autoimmunity in the immunopathogenesis of chronic allograft rejection. Int J Immunogenet (2012) 0.86
Antibodies to MHC class II molecules induce autoimmunity: critical role for macrophages in the immunopathogenesis of obliterative airway disease. PLoS One (2012) 0.86
Effects of preexisting autoimmunity on heart graft prolongation after donor-specific transfusion and anti-CD154. Transplantation (2014) 0.84
Pre-transplant antibodies to Kα1 tubulin and collagen-V in lung transplantation: clinical correlations. J Heart Lung Transplant (2013) 0.83
Significance of T helper 17 immunity in transplantation. Curr Opin Organ Transplant (2012) 0.82
Inhibition of renin angiotensin aldosterone system causes abrogation of obliterative airways disease through inhibition of tumor necrosis factor-α-dependant interleukin-17. J Heart Lung Transplant (2012) 0.81
Anti-major histocompatibility complex-induced obliterative airway disease: selective role for CD4 and CD8 T cells in inducing immune responses to self-antigens. J Heart Lung Transplant (2013) 0.80
Vascular endothelium as a target of immune response in renal transplant rejection. Front Immunol (2014) 0.80
Nitric oxide sustains IL-1β expression in human dendritic cells enhancing their capacity to induce IL-17-producing T-cells. PLoS One (2015) 0.79
Lung transplantation: chronic allograft dysfunction and establishing immune tolerance. Hum Immunol (2014) 0.79
Humoral immunity and the development of obliterative bronchiolitis after lung transplantation: is there a link? Am J Respir Cell Mol Biol (2012) 0.79
Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by Anti-MHC I antibodies. Transplantation (2013) 0.79
Complement activation is not required for obliterative airway disease induced by antibodies to major histocompatibility complex class I: Implications for chronic lung rejection. J Heart Lung Transplant (2012) 0.78
Role of antibodies to self-antigens in chronic allograft rejection: potential mechanism and therapeutic implications. Hum Immunol (2012) 0.78
Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients. J Heart Lung Transplant (2014) 0.78
Long-Term Persistence of Donor Alveolar Macrophages in Human Lung Transplant Recipients That Influences Donor-Specific Immune Responses. Am J Transplant (2016) 0.78
De novo development of antibodies to kidney-associated self-antigens angiotensin II receptor type I, collagen IV, and fibronectin occurs at early time points after kidney transplantation in children. Pediatr Transplant (2015) 0.77
Lung transplantation. F1000Prime Rep (2013) 0.77
Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation. J Am Soc Nephrol (2016) 0.76
Lung-Restricted Antibodies Mediate Primary Graft Dysfunction and Prevent Allotolerance after Murine Lung Transplantation. Am J Respir Cell Mol Biol (2016) 0.76
De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II. J Immunol (2015) 0.76
Basement membranes and autoimmune diseases. Matrix Biol (2016) 0.75
Antibodies against Apoptotic Cells Present in End-stage Lung Disease Patients Do Not Correlate with Clinical Outcome after Lung Transplantation. Front Immunol (2017) 0.75
Elevated Circulating Interleukin 33 Levels in Stable Renal Transplant Recipients at High Risk for Cardiovascular Events. PLoS One (2015) 0.75
Lung Injury Combined with Loss of Regulatory T Cells Leads to De Novo Lung-Restricted Autoimmunity. J Immunol (2016) 0.75
Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection. J Immunol Res (2017) 0.75
Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation. Front Immunol (2016) 0.75
Protein-DNA array-based identification of transcription factor activities differentially regulated in obliterative bronchiolitis. Int J Clin Exp Pathol (2015) 0.75
Immune Responses to Tissue-Restricted Nonmajor Histocompatibility Complex Antigens in Allograft Rejection. J Immunol Res (2017) 0.75
Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop. JCI Insight (2017) 0.75
Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2007) 6.67
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant (1996) 3.51
IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest (2007) 3.31
De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol (2008) 1.95
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol (2009) 1.74
J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg (2004) 1.73
Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol (2002) 1.68
CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant (2006) 1.63
Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol (2007) 1.58
Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation (2001) 1.52
Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol (2003) 1.50
The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation (2005) 1.46
HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation (1998) 1.41
The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc (1997) 1.39
Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol (2006) 1.31
Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant (2005) 1.31
Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J Immunol (1998) 1.30
Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation (1999) 1.28
Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol (2004) 1.24
Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation (2002) 1.17
Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group. Ann Thorac Surg (1995) 1.15
Bronchiolitis obliterans following lung transplantation. Eur J Cardiothorac Surg (2006) 1.12
C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol (2005) 1.00
Temporal relationship between the development of anti-HLA antibodies and the development of bronchiolitis obliterans syndrome after lung transplantation. Transplant Proc (1999) 1.00
Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant (2001) 1.00
Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant (2004) 1.00
Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am J Transplant (2003) 0.97
Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant (2003) 0.92
Molecular mechanisms of chronic rejection following transplantation. Immunol Res (2005) 0.90
Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts. Transplant Proc (1993) 0.85
The role of heat shock protein 27 in bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant (2010) 0.83
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med (2008) 4.70
Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med (2006) 2.69
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest (2006) 2.33
HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A (2008) 2.31
Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg (2010) 2.31
Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg (2012) 2.22
Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg (2002) 2.19
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog (2009) 2.15
Autoantibody formation after alloimmunization: are blood transfusions a risk factor for autoimmune hemolytic anemia? Transfusion (2004) 2.06
Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg (2010) 2.06
De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol (2008) 1.95
Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med (2004) 1.95
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol (2007) 1.88
Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg (2002) 1.86
Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thorac Cardiovasc Surg (2003) 1.80
Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol (2009) 1.74
Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs. J Immunol (2009) 1.64
Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation. Ann Thorac Surg (2006) 1.63
Functional equivalence and evolutionary convergence in complex communities of microbial sponge symbionts. Proc Natl Acad Sci U S A (2012) 1.63
Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol (2005) 1.61
Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg (2011) 1.59
CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol (2004) 1.56
Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation (2007) 1.54
Potential for detrimental hyperinflation after lung transplantation with application of negative pleural pressure to undersized lung grafts. J Thorac Cardiovasc Surg (2003) 1.54
Sternoclavicular joint infection: a comparison of two surgical approaches. Ann Thorac Surg (2011) 1.52
Inhibition of nuclear factor kappaB by IkappaB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg (2005) 1.52
A prospective evaluation of lung volume reduction surgery in 200 consecutive patients. Chest (2003) 1.51
The accuracy of dermatology network physician directories posted by Medicare Advantage health plans in an era of narrow networks. JAMA Dermatol (2014) 1.50
Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg (2008) 1.50
Benefits of resection for metachronous lung cancer. J Thorac Cardiovasc Surg (2004) 1.50
Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol (2003) 1.50
Prevalence of benign disease in patients undergoing resection for suspected lung cancer. Ann Thorac Surg (2006) 1.46
Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol (2003) 1.46
The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation (2005) 1.46
Esophageal carcinoma with celiac nodal metastases; curative or palliative? J Thorac Oncol (2008) 1.44
Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest (2013) 1.42
Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant (2010) 1.41
Nonoperative management of large tracheal injuries. J Thorac Cardiovasc Surg (2008) 1.40
Results of lung volume reduction surgery in patients meeting a national emphysema treatment trial high-risk criterion. J Thorac Cardiovasc Surg (2004) 1.39
Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant (2010) 1.35
Telephone-based coping skills training for patients awaiting lung transplantation. J Consult Clin Psychol (2006) 1.33
Outcomes after resection of giant emphysematous bullae. Ann Thorac Surg (2004) 1.33
Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants. Am J Respir Cell Mol Biol (2007) 1.33
Bronchial fenestration improves expiratory flow in emphysematous human lungs. Ann Thorac Surg (2003) 1.32
Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg (2010) 1.32
Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol (2006) 1.31
Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant (2005) 1.31
Orthotopic mouse lung transplantation as experimental methodology to study transplant and tumor biology. Nat Protoc (2009) 1.30
Lymph node evaluation in video-assisted thoracoscopic lobectomy versus lobectomy by thoracotomy. Ann Thorac Surg (2010) 1.29
Effects of CT section thickness and reconstruction kernel on emphysema quantification relationship to the magnitude of the CT emphysema index. Acad Radiol (2010) 1.26
Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg (2008) 1.24
Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg (2006) 1.24
Thirteen-year experience in lung transplantation for emphysema. Ann Thorac Surg (2002) 1.21
A simple, reproducible, and inexpensive technique in the preparation of explanted emphysematous lungs for ex vivo studies. J Thorac Cardiovasc Surg (2005) 1.16
Short- and long-term outcomes of 1000 adult lung transplant recipients at a single center. J Thorac Cardiovasc Surg (2010) 1.15
Prolonged cold-preservation of nerve allografts. Muscle Nerve (2005) 1.14
CD4+ T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants. J Immunol (2008) 1.14
ATHLATES: accurate typing of human leukocyte antigen through exome sequencing. Nucleic Acids Res (2013) 1.13
Outcomes and perception of lung surgery with implementation of a patient video education module: a prospective cohort study. J Am Coll Surg (2012) 1.13
Use of an apical heart suction device for exposure in lung transplantation. Ann Thorac Surg (2006) 1.13
Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival. Ann Thorac Surg (2011) 1.12
Marine microbial symbiosis heats up: the phylogenetic and functional response of a sponge holobiont to thermal stress. ISME J (2013) 1.12
Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther (2012) 1.11
Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant (2004) 1.10
Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer. Int J Cancer (2002) 1.10
Oxidative damage to nucleic acids in severe emphysema. Chest (2008) 1.10
Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann Thorac Surg (2013) 1.10
Airway epithelium is the primary target of allograft rejection in murine obliterative airway disease. Am J Transplant (2004) 1.09
Effects of Schwann cells and donor antigen on long-nerve allograft regeneration. Microsurgery (2005) 1.08
Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg (2002) 1.08
Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc Surg (2005) 1.06
Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation. Hum Immunol (2010) 1.05
Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer (2005) 1.05
The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology (2009) 1.05
Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant (2008) 1.05